![Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism**Supported by an educational grant from TAP Pharmaceuticals, Deerfield, Illinois (K.E.H.) and by the Division of Research Resources of the National Institutes of Health under grant MO1RR00350, Bethesda, Maryland.††Presented in part at the 27th Annual Meeting of The American Fertility Society, San Antonio, Texas, November 5 to 10, 1994.]()
Combination gonadotropin-releasing hormone agonist and oral contraceptive therapy improves treatment of hirsute women with ovarian hyperandrogenism**Supported by an educational grant from TAP Pharmaceuticals, Deerfield, Illinois (K.E.H.) and by the Division of Research Resources of the National Institutes of Health under grant MO1RR00350, Bethesda, Maryland.††Presented in part at the 27th Annual Meeting of The American Fertility Society, San Antonio, Texas, November 5 to 10, 1994.Elkind-Hirsch, Karen E.; Anania, Carol; Mack, Marie; Malinak, Russell · Fertility and Sterility · 1995